NeuroSense Therapeutics Ltd NRSN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones
-
NeuroSense Provides Update on Nasdaq Listing Compliance
-
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
-
NeuroSense Provides Business Update and Progress for the First Half of 2026
-
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
-
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
-
NeuroSense Issues CEO Letter to Shareholders
-
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 1.90M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 16
- Website
- https://www.neurosense-tx.com
Valuation
|
Metric
|
NRSN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NRSN
|
|---|---|
Quick Ratio | 0.26 |
Current Ratio | 0.28 |
Interest Coverage | −115.03 |
Quick Ratio
NRSN
Profitability
|
Metric
|
NRSN
|
|---|---|
Return on Assets (Normalized) | −769.79% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
NRSN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|ZWhZ<!$ | LOCK|%qDCs | $123B | |||
| Moderna Inc
MRNA
| LOCK|k&?DyH | LOCK|?f | $86B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|lL&L&D@ | LOCK|m&!#> | $78B | |||
| argenx SE ADR
ARGX
| LOCK|@qdFPnJ | LOCK|Px | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|hz^>R< | LOCK|&N | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|p$mdFHD | LOCK|&wj< | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^<!%%@sx | LOCK|CH>w! | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|j@^Z$%q | LOCK|cGD | $22B | |||
| Incyte Corp
INCY
| LOCK|Nh@GX^S | LOCK|$?p | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|$Q^v$wr | LOCK|wqj | $14B |
United States